The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD. 

There has been evidence that patients being treated with chemoradiation for Non-Small Cell Lung Cancer (NSCLC) have experienced cardiac toxicities (heart damage). This study is exploring if testing patients hearts that have been diagnosed with NSCLC before and after treatment can help investigators decrease heart damage for patients in the future.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

This is a 3-part study. The purpose of Part 1 of the study is to evaluate the efficacy, safety, and pharmacokinetic (PK) characteristics of safusidenib in participants with recurrent/progressive IDH1-mutant World Health Organization (WHO) Grade 2 or Grade 3 glioma.The purpose of Part 2 will be to evaluate the efficacy of maintenance safusidenib treatment versus placebo in IDH1-mutant Grade 2 or Grade 3 astrocytoma with high-risk features or IDH1-mutant Grade 4 astrocytoma, following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Part 2 will be randomized, double-blind, and placebo-controlled.The purpose of Part 3 will be to evaluate the efficacy of safusidenib in participants with residual or recurrent IDH1-mutant Grade 3 oligodendroglioma who have received surgery as their only treatment. Part 3 will be an open-label single-arm cohort and will enroll participants concurrently with Part 2.THIS STUDY IS ENROLLING BY INVITATION ONLY

The goal of this study is to examine efficacy of the treatment in individuals with chronic mild TBI and their caregivers and to determine whether patient neurobehavioral functioning moderates the relationship between treatment outcomes and burden in caregivers.  Beyond injury-based cohorts, we sought to examine whether WeCAN would be efficacious in a dementia population, particularly given the neuropathological link that predisposes individuals with TBI to ADRD in later life. THIS STUDY IS ENROLLING BY INVITATION ONLY - Patient/caregiver dyads will be recruited from participating sites. Recruitment will also be conducted via the Kessler Foundation recruitment database, connections with local clinics and support group organizations, posted flyers, and by other methods. At Indiana University (IU), research participants will be recruited from Regenstrief Institute referrals. Recruitment will also be conducted through Franciscan Health’s Comprehensive Outpatient Rehabilitation Program.